

rodents, daily supplementation of 1–2 g resveratrol for 2 weeks or 500 mg for 4 weeks to obese men did not affect the blood pressure, resting energy expenditure, visceral fat contents, and inflammatory biomarkers.<sup>53,54</sup> In addition, non-obese and postmenopausal women with normal glucose tolerance did not respond to daily administration of 75 mg of resveratrol for 12 weeks.<sup>55</sup> A 1 year supplementation of resveratrol-containing (8 mg) grape-extract in coronary artery disease patients increased the level of anti-inflammatory adiponectin and decreased the levels of high-sensitivity C-reactive protein, tumor necrosis factor  $\alpha$ , and thrombogenic plasminogen activator inhibitor type 1.<sup>56,57</sup> Moreover, daily supplementation of 10 mg of resveratrol capsule for 3 months to patients with coronary artery disease after myocardial infarction showed an improvement in the ventricle function and lowered the LDL-cholesterol level.<sup>58</sup> The effect of resveratrol on the host metabolism and clinical trials related to metabolic diseases were well reviewed by Timmers *et al.*<sup>59</sup>

According to the data from these reports, the optimal concentration and duration of resveratrol treatment seem to be distinct for the specific disease. Thus, large-scale and long-term studies are required to further evaluate the clinical values of resveratrol.

### 13.2.4 Putative Target Molecules for Lifespan-Extending Effect of Resveratrol

The first identified molecular target of resveratrol was sirtuin, an NAD<sup>+</sup> dependent deacetylase. However, sirtuins are not the only target of resveratrol, and resveratrol is reported to have numerous molecular targets, including AMP-activated protein kinase (AMPK), cyclooxygenases, lipoxygenases, adenylyl cyclase, DNA polymerase, ribonucleotide reductase, quinone reductase 2, aryl hydrocarbon receptors, cytochrome P450 enzymes, F1-ATPase, and phosphodiesterases.<sup>8,12,60–65</sup> In addition, the metabolic effects of resveratrol were recently reported to be mediated by inhibiting cAMP phosphodiesterases (PDEs), particularly PDE4.<sup>64</sup> The underlying mechanism of lifespan-extending effects by phytochemicals is well reviewed by Leonov *et al.*<sup>1</sup> In this section, we focus on the putative mechanisms of lifespan-extending effects by resveratrol.

#### 13.2.4.1 Caloric Restriction Mimetics

Caloric restriction is defined as the reduction of calorie uptake without malnutrition, and is well established to extend the lifespan of almost all species, including non-human primates. Several studies have shown that resveratrol did not further increase the lifespan under caloric restriction conditions, indicating that caloric restriction and resveratrol share similar anti-aging mechanisms. In 2003, Howitz *et al.* showed that resveratrol did not further extend the lifespan of *S. cerevisiae* under glucose-restricted conditions.<sup>17</sup>